Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liu, Feng ^a   Zhang, Wen ^a,b   Yang, Fusheng ^a   Feng, Tingting ^a   Zhou, Meng ^a   Yu, Yuan ^a   Yu, Xiuping ^a   Zhao, Weiming ^a   Yi, Fan ^a   Tang, Wei ^a   Lu, Yi ^a  

^a SHANDONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GRN PROTEIN, HUMAN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; RAPAMYCIN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ANIMAL; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; LIVER NEOPLASMS; MICE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN;

EID: 84958279314     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21260     Document Type: Article

References (60)

1. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., Jemal, A. Global cancer statistics, 2012. CA Cancer J Clin 65, 87-108 (2015).
2. El-Serag, H. B., Lau, M., Eschbach, K., Davila, J., Goodwin, J. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 167, 1983-9 (2007).
3. El-Serag, H. B. Hepatocellular carcinoma. N Engl J Med 365, 1118-27 (2011).
4. Capece, D. et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013, 187204 (2013).
5. Taniguchi, K., Karin, M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 26, 54-74 (2014).
6. Tilg, H. et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 103, 264-74 (1992).
7. Trikha, M., Corringham, R., Klein, B., Rossi, JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9, 4653-65 (2003).
8. Nakagawa, H. et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 125, 2264-9 (2009).
9. Wong, V. et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 124, 2766-70 (2009).
10. Hrabal, R., Chen, Z., James, S., Bennett, H. P., Ni, F. The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat Struct Biol 3, 747-52 (1996).
11. Tang, W. et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332, 478-84 (2011).
12. Kawase, R. et al. Deletion of progranulin exacerbates atherosclerosis in ApoE knockout mice. Cardiovasc Res 100, 125-33 (2013).
13. Matsubara, T. et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab 15, 38-50 (2012).
14. Wei, F. et al. PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner. Sci Rep 4, 7023 (2014).
15. Zhao, Y. P. et al. Progranulin knockout accelerates intervertebral disc degeneration in aging mice. Sci Rep 5, 9102 (2015).
16. Bateman, A., Bennett, H. P. The granulin gene family: from cancer to dementia. Bioessays 31, 1245-54 (2009).
17. He, Z., Bateman, A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl) 81, 600-12 (2003).
18. Hu, S. Y., Tai, C. C., Li, Y. H., Wu, J. L. Progranulin compensates for blocked IGF-1 signaling to promote myotube hypertrophy in C2C12 myoblasts via the PI3K/Akt/mTOR pathway. FEBS Lett 586, 3485-92 (2012).
19. Chen, X. et al. Gene expression patterns in human liver cancers. Mol Biol Cell 13, 1929-39 (2002).
20. Cheung, S.T. et al. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 10, 7629-36 (2004).
21. Cheung, S. T., Cheung, P. F., Cheng, C. K., Wong, N. C., Fan, S.T. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 140, 344-55 (2011).
22. Frampton, G. et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 61, 268-77 (2012).
23. Bjornsti, M. A., Houghton, P. J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4, 335-48 (2004).
24. Sarbassov, D. D., Guertin, D. A., Ali, S. M., Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-101 (2005).
25. Sieghart, W. et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83, 425-32 (2007).
26. Villanueva, A. et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135, 1972-83 (2008).
27. Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G., Torbenson, M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10, 8421-5 (2004).
28. Semela, D. et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46, 840-8 (2007).
29. Chen, C., Wang, G. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol 7, 1964-70 (2015).
30. Carr, B. I. Hepatocellular carcinoma: current management and future trends. Gastroenterology 127, S218-24 (2004).
31. Llovet, J. M., Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37, 429-42 (2003).
32. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099-109 (2004).
33. Ogasawara, S. et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 5, 850-6 (2011).
34. Ogasawara, S. et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 87, 330-41 (2014).
35. Grivennikov, S. I., Greten, F. R., Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-99 (2010).
36. El-Serag, H. B., Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-76 (2007).
37. Guo, Y., Xu, F., Lu, T., Duan, Z., Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38, 904-10 (2012).
38. Giannitrapani, L. et al. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci 963, 46-52 (2002).
39. Porta, C. et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 19, 353-8 (2008).
40. Soresi, M. et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 12, 2563-8 (2006).
41. Ohishi, W. et al. Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study. Int J Cancer 134, 154-63(2014).
42. Jang, J. W. et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 60, 686-93 (2012).
43. Garbers, C. et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 23, 85-97(2012).
44. Kishimoto, T. IL-6: from its discovery to clinical applications. Int Immunol 22, 347-52 (2010).
45. Nakajima, T. et al. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA 90, 2207-11 (1993).
46. Piwien Pilipuk, G., Galigniana, M. D., Schwartz, J. Subnuclear localization of C/EBP beta is regulated by growth hormone and dependent on MAPK. J Biol Chem 278, 35668-77 (2003).
47. Bhandari, V., Daniel, R., Lim, P. S., Bateman, A. Structural and functional analysis of a promoter of the human granulin/epithelin gene. Biochem J 319, 441-7 (1996).
48. Zanocco-Marani, T., Bateman, A., Romano, G., Valentinis, B., He, Z. H., Baserga, R. Biological activities and signaling pathways of the granulin/epithelin precursor. Cancer Res 59, 5331-40 (1999).
49. Frampton, G. et al. The novel growth factor, progranulin, stimulates mouse cholangiocyte proliferation via sirtuin-1-mediated inactivation of FOXO1. Am J Physiol Gastrointest Liver Physiol 303, G1202-11 (2012).
50. Guertin, D. A. et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11, 859-71 (2006)
51. Jacinto, E. et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-37 (2006).
52. Zhao, Y., Wang, Y., Zhu, W. G. Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol 3, 276-82 (2011).
53. Motta, M. C. et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 116, 551-63 (2004).
54. Qiang, L., Banks, A. S., Accili, D. Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J Biol Chem 285, 27396-401 (2010).
55. Buitrago-Molina, L. E., Vogel, A. mTor as a potential target for the prevention and treatment of hepatocellular carcinoma. Curr Cancer Drug Targets 12, 1045-61 (2012)
56. Matter, M. S., Decaens, T., Andersen, J. B., Thorgeirsson, S. S. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 60, 855-65 (2014).
57. Geng, J. et al. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma. Technol Cancer Res Treat 13, 377-85 (2014).
58. Ong, L. C. et al. Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model. Mol Imaging Biol 11, 334-42 (2009).
59. Lu, Y. et al. Growth factor progranulin contributes to cervical cancer cell proliferation and transformation in vivo and in vitro. Gynecol Oncol 134, 364-71 (2014).
60. Zhou, M. et al. Progranulin protects against renal ischemia/reperfusion injury in mice. Kidney Int 87, 918-29 (2015).